CIPLA LTD vs Centuple Global Ltd
A side-by-side comparison of CIPLA LTD (CIPLA) and Centuple Global Ltd (RUBRAMEDICAMENTSLTD) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs RUBRAMEDICAMENTSLTD on 8 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability22
- Growth01
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
RUBRAMEDICAMENTSLTD takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Stock is trading at 0.87 times its book value", "Company's median sales growth is 26.2% of last 10 years", "Company's working capital requirements have reduced from 182 days to 14.7 days"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 12.3% over last 3 years.", "Company might be capitalizing the interest cost", "Company has high debtors of 215 days."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.